Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence and risks of intravenous chemotherapy-induced severe neutropenia in solid cancers: a multicenter retrospective cohort study on real-life data.
Rohr O, Priou S, Chatellier G, Babai S, Gallien S, Flicoteaux R, Tournigand C, Kempf E; Assistance Publique –Hôpitaux de Paris (AP-HP) Cancer Group, a CRAB* project. Rohr O, et al. Among authors: tournigand c. Support Care Cancer. 2024 Sep 13;32(10):657. doi: 10.1007/s00520-024-08817-4. Support Care Cancer. 2024. PMID: 39269541
Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial.
Alexandre J, Oudard S, Golmard L, Campedel L, Mseddi M, Ladoire S, Khalil A, Maillet D, Tournigand C, Pasquiers B, Goirand F, Berthier J, Guitton J, Dariane C, Joly F, Xylinas E, Golmard JL, Abdoul H, Puszkiel A, Decleves X, Carton E, Thomas A, Vidal M, Huillard O, Blanchet B. Alexandre J, et al. Among authors: tournigand c. Clin Pharmacokinet. 2024 Jul;63(7):1025-1036. doi: 10.1007/s40262-024-01396-x. Epub 2024 Jul 4. Clin Pharmacokinet. 2024. PMID: 38963459 Clinical Trial.
Management of biliary tract cancers in early-onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort.
Lebeaud A, Antoun L, Paccard JR, Edeline J, Bourien H, Fares N, Tournigand C, Lecomte T, Tougeron D, Hautefeuille V, Viénot A, Henriques J, Williet N, Bachet JB, Smolenschi C, Hollebecque A, Macarulla T, Castet F, Malka D, Neuzillet C, Vernerey D, Boilève A, Turpin A. Lebeaud A, et al. Among authors: tournigand c. Liver Int. 2024 Aug;44(8):1886-1899. doi: 10.1111/liv.15922. Epub 2024 Apr 8. Liver Int. 2024. PMID: 38588031
Hospital end-of-life care aggressiveness in adult solid tumour patients pre and post COVID-19: retrospective multicentre cohort study.
Cassam Chenai T, El Mejdani M, Cohen A, Priou S, Chatellier G, Flicoteaux R, Mhalla A, Tournigand C, Kempf E, Lamé G; Assistance Publique – Hôpitaux de Paris (AP-HP) Cancer Group, a CRAB* initiative. Cassam Chenai T, et al. Among authors: tournigand c. BMJ Support Palliat Care. 2024 Mar 27:spcare-2024-004888. doi: 10.1136/spcare-2024-004888. Online ahead of print. BMJ Support Palliat Care. 2024. PMID: 38538033 No abstract available.
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
Blanchet B, Xu-Vuilard A, Jouinot A, Puisset F, Combarel D, Huillard O, Le Louedec F, Thomas F, Teixeira M, Flippot R, Mourey L, Albiges L, Pudlarz T, Joly C, Tournigand C, Chauvin J, Puszkiel A, Chatelut E, Decleves X, Vidal M, Goldwasser F, Oudard S, Medioni J, Vano YA. Blanchet B, et al. Among authors: tournigand c. Br J Cancer. 2024 Apr;130(6):961-969. doi: 10.1038/s41416-024-02585-y. Epub 2024 Jan 25. Br J Cancer. 2024. PMID: 38272963
Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
Calderaro J, Ghaffari Laleh N, Zeng Q, Maille P, Favre L, Pujals A, Klein C, Bazille C, Heij LR, Uguen A, Luedde T, Di Tommaso L, Beaufrère A, Chatain A, Gastineau D, Nguyen CT, Nguyen-Canh H, Thi KN, Gnemmi V, Graham RP, Charlotte F, Wendum D, Vij M, Allende DS, Aucejo F, Diaz A, Rivière B, Herrero A, Evert K, Calvisi DF, Augustin J, Leow WQ, Leung HHW, Boleslawski E, Rela M, François A, Cha AW, Forner A, Reig M, Allaire M, Scatton O, Chatelain D, Boulagnon-Rombi C, Sturm N, Menahem B, Frouin E, Tougeron D, Tournigand C, Kempf E, Kim H, Ningarhari M, Michalak-Provost S, Gopal P, Brustia R, Vibert E, Schulze K, Rüther DF, Weidemann SA, Rhaiem R, Pawlotsky JM, Zhang X, Luciani A, Mulé S, Laurent A, Amaddeo G, Regnault H, De Martin E, Sempoux C, Navale P, Westerhoff M, Lo RC, Bednarsch J, Gouw A, Guettier C, Lequoy M, Harada K, Sripongpun P, Wetwittayaklang P, Loménie N, Tantipisit J, Kaewdech A, Shen J, Paradis V, Caruso S, Kather JN. Calderaro J, et al. Among authors: tournigand c. Nat Commun. 2023 Dec 14;14(1):8290. doi: 10.1038/s41467-023-43749-3. Nat Commun. 2023. PMID: 38092727 Free PMC article.
Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial.
Neuzillet C, Bouché O, Tournigand C, Chibaudel B, Bauguion L, Bengrine-Lefevre L, Lopez-Trabada Ataz D, Mabro M, Metges JP, Péré-Vergé D, Conroy T, Lièvre A, Andre M, Desseigne F, Goldwasser F, Henriques J, Anota A, Hammel P. Neuzillet C, et al. Among authors: tournigand c. J Natl Compr Canc Netw. 2023 Dec;21(12):1234-1242.e17. doi: 10.6004/jnccn.2023.7065. J Natl Compr Canc Netw. 2023. PMID: 38081120 Clinical Trial.
179 results